India produces 100 million doses of the Russian vaccine against Corona
The Russian Sovereign Fund announced the conclusion of an agreement with the Indian "Hetero" pharmaceutical group to produce more than one hundred million annual doses of the Russian "Sputnik-V" vaccine against the emerging corona virus (Covid-19).
The sovereign fund that financed the development of the vaccine said in a statement: "Hetero, one of the major Indian groups that manufactures generic drugs, has agreed to produce more than a hundred million doses (of Sputnik-V) per year in India," indicating that the vaccine production process will start in early 2021 ".
The statement indicated that clinical trials of the vaccine in the second and third stages are currently underway in India.
"Thanks to our cooperation with Hetero, we will be able to significantly increase production capacity and provide an effective solution to the people of India in this difficult phase of the epidemic," said Kirill Dmitriev, head of the sovereign fund.
The sovereign fund indicated that it had received "requests" for more than 1.2 billion doses of the "Sputnik-V" vaccine from "more than fifty countries."
Russia had confirmed that its vaccine, developed by the "Gamalia" Research Center in Moscow, is 95% effective, which is similar to the effectiveness of the two vaccines developed by the Pfizer / Biontech Alliance and the American company Moderna.
The "Sputnik-V" vaccine is currently in the third phase of clinical trials that are conducted according to an experimental approach in which neither the patient nor the doctor knows whether the given vaccine is real or fake.
The experiments include forty thousand volunteers.
Follow our latest local and sports news, and the latest political and economic developments via Google news